Home / Market News / $VKTX
benzinga Corporate Catalyst Impact 85/100 ● neutral

Viking Therapeutics Initiates SUNRISE Phase 3 Clinical Program For Oral VK2735 Dual Agonist Of GLP-1 And Glucose-Dependent Insulinotropic Polypeptide Receptors

Oct 14, 2026, 11:09 AM UTC · Primary ticker $VKTX

Viking Therapeutics has initiated its SUNRISE Phase 3 clinical program for oral VK2735, a dual GLP-1 and GIP receptor agonist, targeting obesity and obesity with type 2 diabetes. This marks a significant advancement for the company, moving its promising oral drug candidate into late-stage trials, which could have substantial implications for the competitive obesity drug market.

Viking Therapeutics has announced the initiation of its SUNRISE Phase 3 clinical program for oral VK2735, a dual GLP-1 and GIP receptor agonist. This is a critical development as it moves their oral obesity drug candidate into late-stage trials, a significant de-risking event for the company. If successful, VK2735 could become a major competitor in the rapidly growing obesity and metabolic disorders market, currently dominated by injectables from Eli Lilly (LLY) and Novo Nordisk (NVO). For VKTX, this represents a long-term opportunity for substantial revenue growth, while for LLY and NVO, it poses a potential threat of increased competition, particularly in the oral drug segment. Traders should watch for initial enrollment progress and future data readouts as these will be key catalysts.

$VKTX positive Advancement of key drug candidate into Phase 3
$LLY negative Increased competition in obesity drug market
$NVO negative Increased competition in obesity drug market
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.